Platelet-rich Plasma vs. Hyaluronic Acid for Glenohumeral Osteoarthritis

• Status: Completed
• Trial end date: 2020-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study seeks to expand the current literature in demonstrating potentially efficacious, conservative treatments in the management of glenohumeral osteoarthritis (OA) and will compare ultrasound-guided injections of hyaluronic acid vs. platelet-rich plasma. We aim to obtain information measuring potential benefits of these interventions and to observe for any adverse events.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital for Special Surgery, New York
• Treatments: Hyaluronic Acid

Criteria

Inclusion Criteria:

• English speaking/literate

• Age 18-100 years

• Visual analog score pain >= 5

• Greater than or equal to 3 months of pain after onset of symptoms that has failed conservative treatments

• Confirmation of glenohumeral OA via routine imaging (MRI and x-ray; must be recent and within the past year)

• Transient relief of symptoms after diagnostic intra-articular injection into the glenohumeral joint

Exclusion Criteria:

• Non-English speaking/illiterate

• Painful active, concurrent cervical spine conditions

• Current non-steroidal anti-inflammatory drug (NSAID) use

• History of taking coumadin or similar anticoagulant, have a known coagulopathy, bleeding dyscrasia, or platelet count < 150,000/cubic mm

• Allergic reaction to poultry or previous viscosupplementation

• Involved in workers' compensation or active litigation involving affected shoulder

• Inability to refrain from NSAID use for 5 days prior to and 6 weeks after injection

• History of corticosteroid injection to affected shoulder within the last 3 months

• History of viscosupplementation or platelet-rich plasma to affected shoulder within the last 6 months

• Presence of acute fracture

• History of shoulder tumor

• Known uncontrolled systemic illness (uncontrolled diabetes, human immunodeficiency virus, vasculitis, autoimmune/inflammatory disease)

• Psychiatric and somatoform disorders